RankAlpha logo
Back to Rankings

MYGN

Myriad GeneticsF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
+
Peers tracked
8
U.S. public peers
Grade Position
Below peers
vs peer average
MYGN vs peer average
15/100
MYGN vs. peer average (F vs. B)
Grade spread
A 4 · B 2 · C 1 · D 1
Graded peers loaded
Coverage
8 graded
100% of tracked

Peer overview

EOLS is the first available peer comparator.

Same sector: Pharmaceuticals, Biotechnology & Life Sciences · Cap $406.32M

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerEOLSEvolus
MYGN
Myriad Genetics
EOLS
Evolus
Grade
F
A
Momentum
6
91
Value
41
41
Sentiment
-
-
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Defensive
Constructive
Open Side-by-Side ComparisonCompare all

Grade position vs EOLS

MYGN / EOLS
Grade Position
Below peers
MYGN vs. peer average (F vs. B)
15/100
Momentum
6
EOLS
Value
41
MYGN
Sentiment
-
-

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs MYGN
1
EOLS
Evolus Inc Common
A
100/100
-4
2
STRO
Sutro Biopharma Inc Common
A
100/100
-4
3
MNPR
Monopar Therapeutics Inc Common
A
100/100
-4
4
CATX
Perspective Therapeutics Inc Common
D
40/100
-1
5
ADCT
ADC Therapeutics Ltd Common
C
60/100
-2
EOLS is the first peer returned for this comparison set.